Axsome Therapeutics
AXSM
129.36
-6.32
-4.66%
Axsome Therapeutics
US · AXSM
#1533 by market cap
Listed 2015
129.36
-6.32
-4.66%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 11 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.3 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 91.63% +1.32pp
- Institutions
- 604 -11
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund55.40%
Private Company15.93%
Hedge Fund11.85%
Public Company2.80%
VC/PE Fund2.31%
Government Pension Fund1.92%
Individual/Insider1.06%
Sovereign Wealth Fund0.98%
Insurance Company0.22%
Other7.54%
Top holders as of 2026-04-14
Antecip Capital, L.L.C.
13.96% · 7.34M sh
BlackRock
6.56% · 3.45M sh
Vanguard Capital Management, LLC
3.82% · 2.01M sh
Vanguard Portfolio Management, LLC
3.75% · 1.97M sh
Invesco Ltd.
3.03% · 1.59M sh
FMR
2.74% · 1.44M sh
Geode Capital Management, LLC
1.92% · 1.01M sh
UBS Asset Management
1.86% · 976.94K sh
Morgan Stanley
1.41% · 736.01K sh
State Street Global Advisors
1.57% · 823.33K sh
Franklin Resources
1.42% · 746.25K sh
Deep Track Capital, LP
1.34% · 700.00K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 21 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| Antecip Capital, L.L.C. | -- | 13.96% |
| Mark Coleman | Lead Independent Director | 0.83% |
| Roger Jeffs | Independent Director | 0.11% |
| Nick Pizzie | Chief Financial Officer | 0.08% |
| Mark Saad | Independent Director | 0.02% |
| Herriot Tabuteau | Chairperson & CEO | 0.01% |
| Susan Mahony | Independent Director | 0.00% |
| Ari Maizel | Chief Commercial Officer | -- |
| Mark Jacobson | Chief Operating Officer | -- |
| Hunter Murdock | General Counsel | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-02 | Mark Jacobson | Chief Operating Officer | Derivative Exercise and Sale | -10,000 | $12.95–208.65 |
| 2026-08-05 | Herriot Tabuteau | Chairperson & CEO | Derivative Exercise and Sale | -49,664 | $4.95–213.95 |
| 2026-08-05 | Herriot Tabuteau | Chairperson & CEO | Intent to Sell (Form 144) | -4,660 | $210.13 |
| 2026-08-04 | Herriot Tabuteau | Chairperson & CEO | Intent to Sell (Form 144) | -45,004 | $212.85 |
| 2026-06-30 | Herriot Tabuteau | Chairperson & CEO | Derivative Exercise and Sale | -49,666 | $4.95–240.25 |
| 2026-06-10 | Roger Jeffs | Independent Director | Automatic Disposition | -572 | $246.18–249.12 |
| 2026-06-10 | Roger Jeffs | Independent Director | Intent to Sell (Form 144) | -286 | $249.12 |
| 2026-06-09 | Roger Jeffs | Independent Director | Intent to Sell (Form 144) | -286 | $246.18 |
| 2026-06-09 | Susan Mahony | Independent Director | Derivative Exercise and Sale | -600 | $237.21–246.18 |
| 2026-06-09 | Susan Mahony | Independent Director | Intent to Sell (Form 144) | -300 | $246.18 |
| 2026-06-09 | Mark Coleman | Lead Independent Director | Derivative Exercise and Sale | -643 | $249.00 |
| 2026-06-09 | Mark Coleman | Lead Independent Director | Intent to Sell (Form 144) | -643 | $249.00 |
| 2026-06-08 | Herriot Tabuteau | Chairperson & CEO | Derivative Exercise and Sale | -49,670 | $4.95–241.01 |
| 2026-06-08 | Susan Mahony | Independent Director | Intent to Sell (Form 144) | -300 | $237.21 |
| 2026-06-08 | Nick Pizzie | Chief Financial Officer | Derivative Exercise and Sale | -33,000 | $3.50–240.09 |
| 2026-06-07 | Roger Jeffs | Independent Director | Derivative Exercise and Retained | +1,429 | -- |
| 2026-06-07 | Mark Saad | Independent Director | Derivative Exercise and Retained | +1,429 | -- |
| 2026-06-07 | Susan Mahony | Independent Director | Derivative Exercise and Retained | +829 | -- |
| 2026-06-07 | Mark Coleman | Lead Independent Director | Derivative Exercise and Retained | +786 | -- |
| 2026-06-04 | Roger Jeffs | Independent Director | Other Derivative Acquisition | +1,721 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Axsome Therapeutics discussion 0 comments